Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add filters








Year range
1.
Journal of the ASEAN Federation of Endocrine Societies ; : 53-56, 2018.
Article in English | WPRIM | ID: wpr-961491

ABSTRACT

@#We present a case of a 27-year-old female with T2 DM who developed allergic reactions after commencement of insulin therapy. Trial with different types of insulin resulted in a series of allergic reactions ranging from urticarial rash to development of angioedema, bronchospasm and anaphylactic shock. She was successfully treated with a modified insulin desensitization protocol using rapid-acting insulin.


Subject(s)
Excipients
2.
Chinese Journal of Clinical Nutrition ; (6): 226-232, 2017.
Article in Chinese | WPRIM | ID: wpr-615204

ABSTRACT

Objective To investigate clinical and pathological characteristics of insulin-induced localized lipoatrophy and treatment.Methods We retrospectively analyzed clinical manifestation, skin biopsy pathology, treatment regimen and follow-up of 6 diabetic patients with insulin-induced localized lipoatrophy in Peking Union Medical College Hospital from January, 2010 to March, 2016, with systemic review of related literatures.Results Among 6 cases with insulin-induced localized lipoatrophy, 5 patients were with insulin allergy.5 patients were with positive insulin-autoimmune antibody, which was similar to the ratio reported in the systematic review (18 out of 19).Insulin-induced lipoatrophy could be caused by various types of preparations of insulin and insulin analogs.Subcutaneous biopsy, performed on the atrophied area, revealed the decrease of the number and volume of adipocytes and tissue fibrosis, probably accompanied with lymphocytes, eosinophils or mast cells infiltration.Lipoatrophy could sometimes be relieved by changing injection sites, types of insulin preparations or drug-delivery way, sometimes by application of systemic/local glucocorticoid or local cromolyn sodium.Conclusions Insulin-induced localized lipoatrophy is a rare adverse reaction of insulin preparations.It might be related to immune response of local tissue and heterogeneous pathological manifestations.The lipoatrophy might be improved by changing injection sites, changing the type of insulin preparations or drug-delivery way, and with possibility to carry out targeted immunosuppressive therapy according to the biopsy pathology in the future.

3.
China Pharmacist ; (12): 907-910, 2017.
Article in Chinese | WPRIM | ID: wpr-610160

ABSTRACT

Objective: To analyze the current situation and treatment strategies of insulin allergy at home and abroad to provide reference for medical staffs to diagnose and treat the anaphylaxis.Methods: The literatures on insulin allergy in recent ten years were searched to analyze the present situation statistically and summarize the treatment strategies.Results: In recent ten years, the cases of insulin allergy were reported repeatedly.The insulin allergy mainly affected skin and its accessories, causing local allergic reactions (redness itching, induration and so on).General allergic reactions occurred rarely, but were life-threatening in severe situations.Conclusion: Medical staffs should grasp the ability of diagnosis and treatment of insulin allergy to ensure the medical safety and effectiveness for patients.

4.
Endocrinology and Metabolism ; : 402-407, 2015.
Article in English | WPRIM | ID: wpr-153714

ABSTRACT

Allergic reaction to insulin is uncommon since the introduction of human recombinant insulin preparations and is more rare in pregnant than non-pregnant females due to altered immune reaction during pregnancy. Herein, we report two cases of allergic reaction to insulin in gestational diabetes that were successfully managed. One case was a 33-year-old female using isophane-neutral protamine Hagedorn human insulin and insulin lispro. She experienced dyspnea, cough, urticaria and itching sensation at the sites of insulin injection immediately after insulin administration. We discontinued insulin therapy and started oral hypoglycemic agents with metformin and glibenclamide. The other case was a 32-year-old female using insulin lispro and insulin detemer. She experienced pruritus and burning sensation and multiple nodules at the sites of insulin injection. We changed the insulin from insulin lispro to insulin aspart. Assessments including immunoglobulin E (IgE), IgG, eosinophil, insulin antibody level and skin biopsy were performed. In the two cases, the symptoms were resolved after changing the insulin to oral agents or other insulin preparations. We report two cases of allergic reaction to human insulin in gestational diabetes due to its rarity.


Subject(s)
Adult , Female , Humans , Pregnancy , Biopsy , Burns , Cough , Diabetes, Gestational , Dyspnea , Eosinophils , Glyburide , Hypersensitivity , Hypersensitivity, Immediate , Hypoglycemic Agents , Immunoglobulin E , Immunoglobulin G , Immunoglobulins , Insulin Aspart , Insulin Lispro , Insulin , Metformin , Pruritus , Sensation , Skin , Urticaria
5.
Chinese Journal of Clinical Nutrition ; (6): 84-86, 2010.
Article in Chinese | WPRIM | ID: wpr-386616

ABSTRACT

Objective To evaluate the values of continuous subcutaneous insulin/rapid insulin analoguc infusion in desensitization for allergy to recombinant human insulin. Methods Two patients allergic to recombinant human insulin received desensitization therapy by continuous subcutaneous insulin lispro infusion. The diluted insulin lispro solution was pumped with initial basal rate of O. O1 U/h, and the basal rate and insulin lispro concentration increased gradually until the insulin dosage for clinical treatment was reached. After that, continuous subcutaneous insulin lispro infusion was replaced by regimen of insulin lispro subcutaneous injection plus oral hypoglycemic agents. Results Local wheals were not observed in both two patients during continuous subcutaneous insulin lispro infusion or during bolus subcutaneous injection of insulin lispro after desensitization. Conclusion The desensitization therapy by continuous subcutaneous insulin/rapid insulin analogue infusion can be applied for allergy to recombinant human insulin.

SELECTION OF CITATIONS
SEARCH DETAIL